- Bone Health
- Immunology
- Hematology
- Respiratory
- Dermatology
- Diabetes
- Gastroenterology
- Neurology
- Oncology
- Ophthalmology
- Rare Disease
- Rheumatology
The Top 5 Biosimilars Articles for the First Half of 2019
The Center for Biosimilars® recaps the 5 most-read stories of 2019 to date.
Transcript
Hi, I’m Samantha DiGrande for The Center for Biosimilars®, your resource for clinical, regulatory, business, and policy news in the rapidly changing world of biosimilars.
It’s been a busy year for biosimilars, and this week, we’re recapping the 5 most-read stories of 2019 to date.
Number 5: The year opened with price hikes to a number of prescription drugs.
Number 4: The FDA approved another biosimilar trastuzumab product referencing Herceptin.
Number 3: Biosimilar developer Pfizer confirmed that it had cut 5 preclinical biosimilar programs from its portfolio.
Number 2: The FDA released its long-awaited final guidance on demonstrating interchangeability.
Number 1: The FDA approved Samsung Bioepis’ trastuzumab biosimilar.
What will the second half of the year hold for biosimilars? Stay up to date with the key news as it unfolds at centerforbiosimilars.com.
Escaping the Void: All Things Biosimilars With Craig & G
May 4th 2025To close out the Festival of Biologics, Craig Burton and Giuseppe Randazzo from the Association for Accessible Medicines and the Biosimilars Council tackle the current biosimilar landscape and how the industry can emerge from the "biosimilar void."
How AI Can Help Address Cost-Related Nonadherence to Biologic, Biosimilar Treatment
March 9th 2025Despite saving billions, biosimilars still account for only a small share of the biologics market—what's standing in the way of broader adoption and how can artificial intelligence (AI) help change that?
